Labopharm, Paladin expand licensing pacts

Labopharm (TSX:DDS; NASDAQ:DDSS) and Paladin Labs (TSX:PLB) have expanded their commercial relationship through three licensing and distribution agreements for two of Labopharm’s products in certain jurisdictions. In the first accord, Labopharm has granted Paladin the exclusive right, subject to Labopharm’s co-promote right for Canada, to market and sell its Intellitab twice-daily formulation of oxycodone-acetaminophen in [...]

Cash-rich Paladin on the acquisition trail

Paladin Labs (TSX:PLB) is sitting on a war chest of some $97 million that’s growing by the quarter and itching to be deployed. “We’re going to invest in opportunities with a high return on investment,” CEO Jonathan Goodman, says in an exclusive interview with biotuesdays.com.  “But I’m not going to bet the company on a [...]